Equities Research Analysts’ Updated EPS Estimates for April 18th (BPTH, EFX, NOA, RLYB, RWT, RZLT, SVRA, TGTX, TWO, VIGL)

Equities Research Analysts’ updated eps estimates for Thursday, April 18th:

Bio-Path (NASDAQ:BPTH) had its buy rating reissued by analysts at Roth Mkm. They currently have a $40.00 price target on the stock.

Equifax (NYSE:EFX) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $305.00 price target on the stock.

North American Construction Group (TSE:NOA) (NYSE:NOA) was upgraded by analysts at TD Securities from a hold rating to a buy rating. TD Securities currently has C$34.00 price target on the stock.

Rallybio (NASDAQ:RLYB) had its market outperform rating reissued by analysts at JMP Securities. JMP Securities currently has a $8.00 target price on the stock.

Redwood Trust (NYSE:RWT) had its market outperform rating reissued by analysts at JMP Securities. The firm currently has a $8.00 target price on the stock.

Rezolute (NASDAQ:RZLT) had its market outperform rating reiterated by analysts at JMP Securities. The firm currently has a $7.00 price target on the stock.

Savara (NASDAQ:SVRA) had its market outperform rating reaffirmed by analysts at JMP Securities. The firm currently has a $8.00 target price on the stock.

TG Therapeutics (NASDAQ:TGTX) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $45.00 target price on the stock.

TG Therapeutics (NASDAQ:TGTX) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $25.00 target price on the stock.

TG Therapeutics (NASDAQ:TGTX) had its buy rating reissued by analysts at LADENBURG THALM/SH SH. The firm currently has a $39.00 target price on the stock.

Two Harbors Investment (NYSE:TWO) had its market outperform rating reaffirmed by analysts at JMP Securities. They currently have a $15.00 price target on the stock.

Vigil Neuroscience (NASDAQ:VIGL) had its market outperform rating reaffirmed by analysts at JMP Securities. They currently have a $23.00 target price on the stock.